BGM vs VTRS Stock Comparison

Bgm and Viatris Prices as of Oct 26, 2026 Peers: Industry group
BGM BGM Group Ltd.
$8.40 +3,400.0% 1M -10.1% 1Y
Market cap
$33.88M
P/E
–
Revenue (TTM)
—
Div. yield
–
Generic Drugs Healthcare
VTRS Viatris Inc
$18.29 +2.6% 1M +76.7% 1Y
Market cap
$21.84B
P/E
–
Revenue (TTM)
$14.74B
Div. yield
–
Generic Drugs Healthcare
3 wins

Head to Head

3 decided of 12

Viatris leads on 3 of the 12 questions below (Viatris 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBGMVTRSLeader
Larger companyMarket capitalisation $33.88M $21.84B VTRS
Cheaper on earningsLower P/E, profitable companies only — -53.2x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 7.0x –
Faster revenue growthRevenue growth, trailing twelve months — +4.4% –
More profitableNet margin, trailing twelve months — -2.8% –
Better return on capitalReturn on invested capital — -0.2% –
Less leveragedLower net debt / EBITDA — 4.6x –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -10.1% +76.7% VTRS
Better 5-year returnAnnualised price return, 5 years — +6.9%/yr –
Less volatileAnnualised volatility, 1 year 380.3% 32.4% VTRS
Higher overall scoreMean of the five percentile scores vs peers — 66/100 –

Percentile Scorecard

BGMVTRS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBGMVTRS
Valuation – 93 #42 of 626
Growth – 47 #318 of 604
Profitability – 81 #106 of 555
Financial Health 60 #264 of 658 23 #510 of 658
Shareholder Returns – 87 #49 of 368
Overall – 66
  • BGM ranked among 673 companies in Pharmaceuticals and Biotechnology
  • VTRS ranked among 673 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBGMVTRSSPY
1 month +3,400.0%+2.6% -0.8%
3 months +2,700.0%+3.7% +3.5%
6 months +2,413.5%+23.5% +7.0%
Year to date +127.6%+46.9% +12.2%
1 year -10.1%+76.7% +13.0%
3 years —+108.6% +86.3%
3 years, per year —+27.8% +23.1%
5 years —+39.6% +68.6%
5 years, per year —+6.9% +11.0%
10 years —-52.0% +258.0%
10 years, per year —-7.1% +13.6%

Risk

MeasureBGMVTRSSPY
Volatility, 1Y 380.3%32.4% 12.7%
Downside volatility, 1Y 158.2%29.6% 12.7%
Beta vs S&P 500, 1Y 1.730.70 1.00
Return / volatility, 1Y -0.032.37 1.02
Max drawdown, 5Y -98.5%-52.9% -25.4%
From 52-week high -21.9%-2.0% -1.8%
52-week high $10.75$18.66 $779.14
52-week low $0.24$10.11 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBGMVTRS
P/E now vs peer median —median 17.1x -51.8xmedian 17.1x
P/S now vs peer median —median 8.8x 1.4xmedian 8.8x
EV/EBITDA now vs peer median —median 17.1x 12.3xmedian 17.1x
P/FCF now vs peer median —median 18.0x 10.7xmedian 18.0x
P/B now vs peer median 0.1xmedian 2.1x 1.5xmedian 2.1x
PEG now vs peer median —median 0.31 1.69median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBGMVTRS
Revenue – $14.74B
Gross profit – $5.13B
Operating income – -$87.30M
Net income – -$410.70M
Free cash flow – $1.95B
R&D – $1.02B
EPS (diluted) – $-0.35
Cash & equivalents $11.52M $886.50M
Total debt $8.25M $13.35B
Shares (diluted) 3.78M 1.16B
Enterprise value -$21.16M $16.85B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBGMVTRS
P/E – -51.8x
P/FCF – 10.7x
P/Operating cash flow – 9.0x
P/S – 1.4x
P/B 0.1x 1.5x
P/Tangible book 0.1x 36.0x
EV/EBITDA – 12.3x
EV/EBIT – -383.4x
EV/Revenue – 2.3x
EV/FCF – 17.1x
EV/Operating cash flow – 14.4x
PEG (3Y EPS CAGR) – 1.69

Growth

14 metrics
MetricBGMVTRS
Revenue growth (1Y) – 4.4%
Revenue CAGR (3Y) – -1.9%
Gross profit growth (1Y) – -0.7%
Gross profit CAGR (3Y) – -6.0%
Operating income growth (1Y) – 96.6%
Operating income CAGR (3Y) – -27.6%
Net income growth (1Y) – 88.2%
Net income CAGR (3Y) – -30.5%
EPS growth (1Y) – 88.1%
EPS CAGR (3Y) – -30.6%
Operating cash flow growth (1Y) – 12.9%
Operating cash flow CAGR (3Y) – -3.0%
Free cash flow growth (1Y) – 11.6%
Free cash flow CAGR (3Y) – -3.6%

Profitability

14 metrics
MetricBGMVTRS
Gross margin – 34.8%
EBITDA margin – 18.4%
Operating margin – -0.6%
Pretax margin – -4.5%
Net margin – -2.8%
FCF margin – 13.3%
Operating cash flow margin – 15.8%
Return on equity – -2.8%
Return on assets – -1.1%
Return on invested capital – -0.2%
Return on capital employed – -0.3%
Asset turnover – 0.4x
Cash conversion (OCF / net income) – -5.7x
Stock comp / revenue – 1.2%

Financial Health

11 metrics
MetricBGMVTRS
Debt / assets 0.2% 38.1%
Debt / equity 0.0x 0.9x
Net debt / EBITDA – 4.6x
Debt / FCF – 6.8x
Liabilities / assets 8.4% 59.3%
Equity / assets 91.6% 40.7%
Interest coverage – -0.2x
Current ratio 1.3x 1.6x
Quick ratio 0.4x 0.7x
Cash ratio 0.3x 0.1x
Altman Z-score – 1.13

Shareholder Returns

7 metrics
MetricBGMVTRS
Dividend yield – 2.6%
Net buyback yield – 1.4%
Shareholder yield 0.0% 4.1%
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBGMVTRS
Forward P/E – 7.0xFY2026
EPS, next fiscal year – $2.62FY2026
EPS growth, next FY – +11.5%FY2026
EPS growth, the year after – -1.5%
Revenue, next fiscal year – $15.31BFY2026
Revenue growth, next FY – +7.0%FY2026
Revenue growth, the year after – -4.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBGMVTRS
Held by institutions – 89.9%
Institutions holding – 1,028
Change in shares held, QoQ – +5.6%
Institutions buying – 486
Institutions selling – 318
Buyers to sellers – 1.53

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BGMVTRS
BGM 1.00 -0.08
VTRS -0.08 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BGM and VTRS?

Viatris (VTRS) is the largest by market capitalisation: Bgm (BGM) $33.88M, Viatris (VTRS) $21.84B.

Which stock has performed better?

Over the past year Viatris (VTRS) returned the most: Bgm (BGM) -10.1%, Viatris (VTRS) +76.7%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Viatris (VTRS) has been the steadiest (Bgm (BGM) 380.3%, Viatris (VTRS) 32.4%). Volatility measures how widely the price swings, not the risk of the business.

Do BGM and VTRS move together?

Their daily returns over the past year have a correlation of -0.08, a negative relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, BGM and VTRS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Viatris (VTRS) leads on 3. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.